Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma.
Ishihara H, Fukuda H, Mizoguchi Y, Yamashita M, Aoki K, Ishiyama R, Ikeda T, Nemoto Y, Shimmura H, Hashimoto Y, Yoshida K, Hirai T, Iizuka J, Tokita D, Kondo T, Nagashima Y, Takagi T. Ishihara H, et al. Among authors: shimmura h. Cancer Immunol Immunother. 2025 Jan 3;74(2):51. doi: 10.1007/s00262-024-03876-2. Cancer Immunol Immunother. 2025. PMID: 39751827 Free PMC article.
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H, Nemoto Y, Nakamura K, Ikeda T, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Takagi T, Ishida H, Kondo T, Tanabe K. Ishihara H, et al. Among authors: shimmura h. Target Oncol. 2021 Jul;16(4):493-502. doi: 10.1007/s11523-021-00825-2. Epub 2021 Jun 26. Target Oncol. 2021. PMID: 34173936
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Ishihara H, et al. Among authors: shimmura h. Target Oncol. 2022 May;17(3):307-319. doi: 10.1007/s11523-022-00879-w. Epub 2022 Apr 23. Target Oncol. 2022. PMID: 35460475
Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yoshino M, Ishihara H, Nemoto Y, Nakamura K, Nishimura K, Tachibana H, Fukuda H, Toki D, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Yoshino M, et al. Among authors: shimmura h. Jpn J Clin Oncol. 2022 Oct 6;52(10):1208-1214. doi: 10.1093/jjco/hyac099. Jpn J Clin Oncol. 2022. PMID: 35780441
Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria.
Nemoto Y, Ishihara H, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Nemoto Y, et al. Among authors: shimmura h. Target Oncol. 2022 Jul;17(4):475-482. doi: 10.1007/s11523-022-00896-9. Epub 2022 Jul 5. Target Oncol. 2022. PMID: 35789472
Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors.
Ishihara H, Ishiyama Y, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Ishihara H, et al. Among authors: shimmura h. Clin Genitourin Cancer. 2023 Feb;21(1):136-145. doi: 10.1016/j.clgc.2022.08.001. Epub 2022 Aug 6. Clin Genitourin Cancer. 2023. PMID: 36031535
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: shimmura h. Target Oncol. 2023 Jan;18(1):159-168. doi: 10.1007/s11523-022-00940-8. Epub 2022 Dec 26. Target Oncol. 2023. PMID: 36571708
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: shimmura h. Target Oncol. 2023 Mar;18(2):209-220. doi: 10.1007/s11523-023-00956-8. Epub 2023 Mar 21. Target Oncol. 2023. PMID: 36941516
106 results